Trials / Terminated
TerminatedNCT04244396
Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study
Persistent AF (Asia Pacific) Observational Study
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 82 (actual)
- Sponsor
- Abbott Medical Devices · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug refractory, symptomatic persistent atrial fibrillation when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures.
Detailed description
The PerAF APAC trial is a prospective, single arm, non-randomized, observational, post-market clinical investigation. Approximately 100 subjects will be enrolled at up to 15 sites in South Korea, Singapore, Hong Kong, Taiwan, and India. Centers in other countries within APAC may be approached for participation in the clinical investigation as needed. Subjects will be followed for 15-months after their initial ablation procedure. The primary effectiveness and safety endpoints will be evaluated through 15-months. A core lab will independently assess AF/Atrial Flutter (AFL)/(Atrial tachycardia (AT) recurrence via Holter monitoring at the 6-month and 15-month follow-up visits. All serious adverse events (SAEs) will be independently adjudicated by qualified physicians not participating in the trial
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) | TactiCath SE is indicated for use in cardiac electrophysiological mapping (stimulation and recording), and, when used in conjunction with a radiofrequency generator, for cardiac ablation of supraventricular arrhythmias in the right and left atrium, including atrial fibrillation. |
Timeline
- Start date
- 2020-02-25
- Primary completion
- 2022-11-30
- Completion
- 2022-11-30
- First posted
- 2020-01-28
- Last updated
- 2024-04-19
- Results posted
- 2024-04-19
Locations
9 sites across 5 countries: Hong Kong, Singapore, South Korea, Taiwan, Thailand
Source: ClinicalTrials.gov record NCT04244396. Inclusion in this directory is not an endorsement.